Cathay Biotech Inc. News

Kaiser Biotech: First Quarter 2025 Report

SZSIApr 29 12:00 ET · Announcements

2025 First Quarter Report

SZSIApr 29 12:00 ET · Announcements

Cathay Biotech Inc. (688065.SH): Breakthrough achieved in the molding process of bio-based polyamide continuous fiber composite materials.

On April 22, Gelonghui reported that Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that the company has made breakthroughs in the forming process of bio-based polyamide continuous fiber composite materials, and has begun to receive commercial Orders in scenarios such as New energy Fund and Logistics. For specific details, please refer to the announcements published by the company on the Shanghai Stock Exchange website.

Gelonghui FinanceApr 22 05:14 ET

Cathay Biotech 2024 Profit Up 33%, Revenue Climbs 40%

MT NewswiresApr 22 01:51 ET

Kaiser Biotech: 2024 Annual Report Summary

SZSIApr 21 12:00 ET · Announcements

Kaiser Biotech: 2024 Annual Report

SZSIApr 21 12:00 ET · Announcements

2024 ANNUAL REPORT

SZSIApr 21 12:00 ET · Announcements

2024 Annual Report Summary

SZSIApr 21 12:00 ET · Announcements

Cathay Biotech Inc. achieved a revenue exceeding 2.9 billion yuan in 2024, with a 40% growth in core product sales.

① In 2024, Cathay Biotech Inc. achieved record high revenue in recent years, and profitability has resumed its growth trajectory; ② This growth is mainly attributed to the decrease in raw material prices and the decline in fixed costs spread over increased production volume. During the reporting period, the long-chain dicarboxylic acid series generated revenue of 2.67 billion yuan, a year-on-year increase of 39.94%, with a gross margin of 39.71%.

cls.cnApr 21 11:17 ET

Cathay Biotech Inc. (688065.SH): A cumulative repurchase of 0.22 million shares.

Gelonghui, April 2nd丨Cathay Biotech Inc. (688065.SH) announced that on March 31, 2025, the company repurchased 220,946 shares through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.0306% of the company's total share capital of 721,289,794 shares. The highest transaction price was 45.95 yuan/share, the lowest price was 44.08 yuan/share, and the total amount paid was 9,995,695.95 yuan (excluding stamp duty, transaction commissions, and other trading fees).

Gelonghui FinanceApr 2 07:31 ET

Cathay Biotech Completes Filing Process to Issue Shares in Shanghai

MT NewswiresMar 28 03:50 ET

Research Reports discovery丨Huaan: Cathay Biotech Inc.’s performance has significantly improved on the margin, maintaining a 'Buy' rating.

Research reports from Huaan highlight that Cathay Biotech Inc. (688065.SH) is expected to achieve a total profit of 0.546 billion yuan in 2024, a year-on-year increase of 21.57%; net income attributable to shareholders is projected to be 0.487 billion yuan, an increase of 32.80% year-on-year, indicating significant marginal improvement in performance and the prominent synergistic effects of the industry chain. The primary reason for growth in 2024 is the recovery in demand for long-chain dicarboxylic acids and the ramp-up of new products for sebacic acid, which will drive high growth in production and sales year-on-year. The company has a clear long-term growth path, and the synergy of technological barriers and policy dividends provides significant long-term advantages. The advantages of the synthetic biology technology platform will release structural dividends driven by Carbon Neutrality goals. In the long term,

Gelonghui FinanceMar 13 03:54 ET

Cathay Biotech Inc. (688065.SH): A total of 0.2209 million company shares have been repurchased.

On March 3, Gelonghui reported that Cathay Biotech Inc. (688065.SH) announced that on February 28, 2025, the company repurchased 220,946 shares through the Shanghai Securities Exchange trading system using a centralized bidding trading method, accounting for 0.0379% of the company's total share capital of 583,378,039 shares. The highest transaction price was 45.95 yuan/share, the lowest was 44.08 yuan/share, and the total funds paid amounted to 9,995,695.95 yuan (excluding transaction fees such as stamp tax and trading commissions).

Gelonghui FinanceMar 3 03:44 ET

Investing in industry funds + establishing a joint venture, Cathay Biotech Inc. "leverages" Contemporary Amperex Technology and Hefei State Assets.

① Behind Cathay Technology are two major giants, Cathay Biotech Inc. and Contemporary Amperex Technology. ② Cathay Technology mainly engages in the research, production, and sales of products applying Cathay Biotech Inc.'s polyamide composite materials in the fields of power batteries, energy storage, and other New energy areas. ③ The招商凯赛新材料基金 (Zhaoshang Cathay New Materials Fund), co-founded by Cathay Biotech Inc., Hefei State-owned Assets, and China Merchants Shekou Industrial Zone Holdings, was established with a registered capital of 0.65 billion yuan.

cls.cnFeb 28 03:32 ET

Cathay Biotech: 2024 Annual Results Report Announcement

SZSIFeb 27 11:00 ET · Announcements

2024 Annual Results Express Announcement

SZSIFeb 27 11:00 ET · Announcements

These 4 Measures Indicate That Cathay Biotech (SHSE:688065) Is Using Debt Reasonably Well

Simply Wall StFeb 19 21:07 ET

Cathay Biotech Inc.'s (SHSE:688065) Share Price Could Signal Some Risk

Simply Wall StJan 29 20:35 ET

Cathay Biotech (SHSE:688065) Will Be Hoping To Turn Its Returns On Capital Around

Simply Wall StJan 8 18:50 ET

Cathay Biotech Inc. (688065.SH): repurchased 0.0379% of the company's shares.

On January 2, Glonghui reported that Cathay Biotech Inc. (688065.SH) announced that as of December 31, 2024, the company repurchased 220,946 shares of its stock through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.0379% of the company's total share capital of 583,378,039 shares. The highest price of the buyback was 45.95 yuan/share, the lowest price was 44.08 yuan/share, and the total funds paid amounted to 9,995,695.95 yuan (excluding stamp duty, transaction commissions, and other transaction costs).

Gelonghui FinanceJan 2 05:25 ET